Drugs /

humax-il8

Back to Drugs List

Overview

NCI Definition [1]:
A human monoclonal antibody against the pro-inflammatory mediator interleukin-8 (IL-8; CXCL8), with potential antineoplastic activities. Upon administration, HuMax-IL8 directly binds to IL-8, thereby inhibiting the binding of IL-8 to its receptors CXCR1 and CXCR2. This inhibits activation of IL-8-mediated signaling transduction pathways, which decreases proliferation of susceptible tumor cells. Also, HuMax-IL8 effectively blocks binding of IL-8 to neutrophils and inhibits neutrophil activation and recruitment towards sites of inflammation, which reduces inflammation. IL-8, a member of the CXC chemokine family, is upregulated in a variety of cancer cell types and inflammatory diseases; it plays a key role in tumor cell proliferation, endothelial cell proliferation, and cancer stem cell (CSC) renewal.

Clinical Trials

View Clinical Trials for humax-il8

Humax-il8 has been investigated in 6 clinical trials, of which 6 are open and 0 are closed. Of the trials investigating humax-il8, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open).

Hepatocellular carcinoma, malignant solid tumor, and melanoma are the most common diseases being investigated in humax-il8 clinical trials [2].

Drug Details

Synonyms [2]:
mdx 018, mdx-018, anti-il-8 monoclonal antibody humax-il8, bms-986253
Drug Target(s) [2]:
IL8
NCIT ID [1]:
C124227

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.